Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms,
but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical
antipsychotics sertindole’s pharmacology, safety and status, and mainly evaluate the effects of sertindole compared with other second
generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis. In vitro studies showed that sertindole exerts
a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and แl adrenergic receptors. Sertindole offers an alternative treatment
option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular
safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents. Further
clinical studies, mainly comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in
the treatment of schizophrenia